NewsHK
Healthcare private equity has been moving at a deliberate pace through this stretch of the deal cycle, and the regulatory calendar for software-driven biopharma tools is now moving to match.
Altaris, the New York-based investment firm managing more than $9 billion in equity capital with a focus exclusively on healthcare, announced Wednesday that the Hart-Scott-Rodino waiting period has expired for its pending acquisition of Simulations Plus, Inc.
(Nasdaq: SLP), clearing one of the key antitrust conditions standing between the two parties and a completed transaction. The expiration was disclosed in an 8-K filing dated August 13, 2026.
The Hart-Scott-Rodino Antitrust Improvements Act of 1976 sets the standard antitrust review mechanism for deals of this scale, and its clearance moves the transaction to its remaining gates.
Keep reading